In vivo effect of insulin to decrease matrix metalloproteinase-2 and-9 activity after arterial injury

Journal of Vascular Research

Volumn 50, Issue 4, 2013, Pages 279-288

  Guo, June ^a   Dhaliwall, Jiwanjeet K ^a   Chan, Kalam K ^a   Ghanim, Husam ^c   Al Koudsi, Nael ^a   Lam, Loretta ^a   Madadi, Golnaz ^a   Dandona, Paresh ^c   Giacca, Adria ^a,b   Bendeck, Michelle P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Arterial injury; Hyperinsulinemia; Insulin; Matrix metalloproteinases; Metabolic syndrome; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; GLUCOSE; INSULIN; MESSENGER RNA; FATTY ACID; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; IN VIVO STUDY; INSULIN TREATMENT; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SMOOTH MUSCLE FIBER; ZYMOGRAPHY; ANIMAL CELL; BALLOON CATHETER; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CAROTID ARTERY INJURY; COMMON CAROTID ARTERY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GENE EXPRESSION; INSULIN BLOOD LEVEL; INSULIN IMPLANT; MOLECULAR WEIGHT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANGIOPLASTY, BALLOON; ANIMALS; BLOOD GLUCOSE; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG IMPLANTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; INSULIN; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; VASCULAR SYSTEM INJURIES;

EID: 84883317687     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000351611     Document Type: Article

References (47)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-1817.
3. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A: Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-2081.
4. Dandona P, Chaudhuri A, Mohanty P, Ghanim H: Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007; 10: 511-517.
5. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101: 676-681.
6. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-1545.
7. Breen DM, Chan KK, Dhaliwall JK, Ward MR, Al Koudsi N, Lam L, De Souza M, Ghanim H, Dandona P, Stewart DJ, Bendeck MP, Giacca A: Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler Thromb Vasc Biol 2009; 29: 1060-1066.
8. Willis AI, Pierre-Paul D, Sumpio BE, Gahtan V: Vascular smooth muscle cell migration: current research and clinical implications. Vasc Endovascular Surg 2004;38:11-23.
9. Newby AC: Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012; 56: 232-244.
10. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ: Matrix metalloproteinases. Br J Surg 1997; 84: 160-166.
11. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539-545.
12. Cho A, Reidy MA: Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002; 91: 845-851.
13. Johnson C, Galis ZS: Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24: 54-60.
14. Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, Itohara S, Iguchi A: Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003; 108: 1375-1381.
15. Wang PY: The reliability of a compressed mixture of insulin and palmitic acid to sustain a reduction in hyperglycemia in rodents. ASAIO Trans 1987; 33: 319-322.
16. Bendeck MP, Irvin C, Reidy MA: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78: 38-43.
17. Bendeck MP, Nakada MT: The beta3 integrin antagonist m7E3 reduces matrix metalloproteinase activity and smooth muscle cell migration. J Vasc Res 2001; 38: 590-599.
18. Breen DM, Dolinsky VW, Zhang H, Ghanim H, Guo J, Mroziewicz M, Tsiani EL, Bendeck MP, Dandona P, Dyck JR, Heximer SP, Giacca A: Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis 2012; 222: 375-381.
19. Kim T, Chan KK, Dhaliwall JK, Huynh N, Suen R, Uchino H, Naigamwalla D, Bendeck MP, Giacca A: Anti-Atherogenic effect of insulin in vivo. J Vasc Res 2005; 42: 455-462.
20. Overall CM, Tam E, McQuibban GA, Morrison C, Wallon UM, Bigg HF, King AE, Roberts CR: Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J Biol Chem 2000; 275: 39497-39506.
21. Caumo A, Luzi L: First-phase insulin secretion: does it exist in real life Considerations on shape and function. Am J Physiol Endocrinol Metab 2004; 287:E371-E385.
22. Lewis GF, Steiner G: Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996; 19: 390-393.
23. McTernan PG, Harte AL, Anderson LA, Green A, Smith SA, Holder JC, Barnett AH, Eggo MC, Kumar S: Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 2002; 51: 1493-1498.
24. Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548-2555.
25. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Cunsolo V, Lauro D, Mauriello A, Smookler DS, Sbraccia P, Sesti G, Lee DC, Khokha R, Accili D, Lauro R: Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-Alpha. J Clin Invest 2005; 115: 3494-3505.
26. Li H, Liang J, Castrillon DH, DePinho RA, Olson EN, Liu ZP: FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2007; 27: 2676-2686.
27. Greer EL, Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-7425.
28. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH: A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003; 369: 485-496.
29. Fini ME, Cook JR, Mohan R, Brinckerhoff CE: Regulation of matrix metalloproteinase gene expression; in Parks WC, Mecham RP (eds): Matrix Metalloproteinases. San Diego, Academic Press, 1998, pp 300-356.
30. Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-B reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells. Cardiovasc Res 2001; 50: 556-565.
31. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
32. Gurjar MV, Sharma RV, Bhalla RC: eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 1999; 19: 2871-2877.
33. Yan Z, Hansson GK: Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ Res 1998; 82: 21-29.
34. Begum N, Ragolia L, Rienzie J, McCarthy M, Duddy N: Regulation of mitogen-Activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension. J Biol Chem 1998; 273: 25164-25170.
35. Cheng TH, Shih NL, Chen SY, Lin JW, Chen YL, Chen CH, Lin H, Cheng CF, Chiu WT, Wang DL, Chen JJ: Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol 2005; 68: 1183-1192.
36. Peng HB, Libby P, Liao JK: Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270: 14214-14219.
37. Eagleton MJ, Peterson DA, Sullivan VV, Roelofs KJ, Ford JA, Stanley JC, Upchurch GR Jr: Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression. J Surg Res 2002; 104: 15-21.
38. Aljada A, Ghanim H, Saadeh R, Dandona P: Insulin inhibits NFB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450-453.
39. Reusch JE, Watson PA: Loss of CREB regulation of vascular smooth muscle cell quiescence in diabetes. Rev Endocr Metab Disord 2004; 5: 209-219.
40. Wang CC, Gurevich I, Draznin B: Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 2003; 52: 2562-2569.
41. Breen DM, Dhaliwall JK, Chan KK, Guo J, Lam L, Bendeck MP, Giacca A: Insulin inhibits and oral sucrose increases neointimal growth after arterial injury in rats. J Vasc Res 2010; 47: 412-422.
42. Murthy SN, Sukhanov S, McGee J, Greco JA, Chandra S, Delafontaine P, Kadowitz PJ, Mc-Namara DB, Fonseca VA: Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Mol Cell Biochem 2009; 330: 1-8.
43. Murthy SN, Pankey EA, Banka AA, Badejo AM Jr, Wekerle R, Vilija V, Izadpanah R, Kadowitz PJ, Fonseca VA: Effects of insulin detemir on balloon catheter injured carotid artery in Zucker fatty rats. J Diabetes Complications 2012; 26: 470-475.
44. Foster E, Zhang S, Kahn AM: Insulin stimulates arterial neointima formation in normal rats after balloon injury. Diabetes Obes Metab 2006; 8: 348-351.
45. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di LE, Stabile E, Perrino C, Chieffo A, Pardo F, Chiariello M: Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 2001; 103: 2980-2986.
46. Pu Q, Chang Y, Zhang C, Cai Y, Hassid A: Chronic insulin treatment suppresses PTP1B function, induces increased PDGF signaling, and amplifies neointima formation in the balloon-injured rat artery. Am J Physiol Heart Circ Physiol 2009; 296:H132-H139.
47. Muniyappa R, Quon MJ: Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007; 10: 523-530.